期刊
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
卷 194, 期 5, 页码 1283-1289出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2005.11.041
关键词
recurrent bacterial vaginosis; suppressive therapy
Objective: Efficacy Study Of Suppressive vaginal metronidazole in reducing recurrent symptomatic episodes of bacterial vaginosis. Study design: Multicenter prospective study with initial 10-day open-label metronidazole gel in which asymptomatic responders randomly assigned to receive twice weekly metronidazole vaginal gel or placebo for 16 weeks and off therapy for 12 weeks. Results: Of 157 eligible women with recurrent bacterial vaginosis, 112 of 127 returning evaluable women (88.2%) responded clinically and were randomly assigned. During suppressive therapy, recurrent bacterial vaginosis occurred in 13 women (25.5%) receiving metronidazole and 26 (59.1%) receiving placebo (MITT analysis, relative risk [RR] 0.43 Cl = 0.25-0.73, P = .001). During the entire 28-week follow-up, recurrence Occurred in 26 (51.0%) on treatment compared with 33 (75%) on placebo (RR 0.68, Cl = 0.49-0.93 P = .02). Probability for remaining cured was 70% for metronidazole compared with 39% on placebo.. which declined to 34% and 18%, respectively, by 28 weeks follow-up. Adverse effects were uncommon; however, secondary vaginal candidiasis occurred significantly more often in metronidazole-treated women (P = .02). Conclusion: Suppressive therapy with twice-weekly metronidazole gel achieves a significant reduction in the recurrence rate of bacterial vaginosis; however, secondary vaginal candidiasis is common. (c) 2006 Mosby, Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据